Myriad Genetics, Inc.
General ticker "MYGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B
Myriad Genetics, Inc. follows the US Stock Market performance with the rate: 10.9%.
Estimated limits based on current volatility of 2.2%: low 13.03$, high 13.63$
Factors to consider:
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [14.66$, 27.33$]
- 2024-12-30 to 2025-12-30 estimated range: [15.53$, 28.47$]
Short-term MYGN quotes
Long-term MYGN plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $690.60MM | $678.40MM | $753.20MM |
| Operating Expenses | $881.10MM | $819.00MM | $1,010.60MM |
| Operating Income | $-190.50MM | $-140.60MM | $-257.40MM |
| Non-Operating Income | $133.40MM | $0.00MM | $-4.80MM |
| Interest Expense | $6.60MM | $3.20MM | $2.90MM |
| R&D Expense | $81.90MM | $85.40MM | $88.70MM |
| Income(Loss) | $-57.10MM | $-140.60MM | $-262.20MM |
| Taxes | $-29.90MM | $-28.60MM | $1.10MM |
| Profit(Loss) | $-27.20MM | $-112.00MM | $-263.30MM |
| Stockholders Equity | $967.80MM | $885.80MM | $783.20MM |
| Inventory | $15.30MM | $20.10MM | $22.00MM |
| Assets | $1,320.70MM | $1,198.70MM | $1,146.50MM |
| Operating Cash Flow | $18.60MM | $-106.30MM | $-110.90MM |
| Capital expenditure | $18.00MM | $45.30MM | $73.30MM |
| Investing Cash Flow | $274.40MM | $-77.50MM | $31.90MM |
| Financing Cash Flow | $-150.60MM | $-8.00MM | $152.90MM |
| Earnings Per Share* | $-0.35 | $-1.39 | $-3.18 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.